NEA, Versant back ophthalmic play Oyster Point with $22M A round

On Nov. 7, ophthalmic play Oyster Point Pharmaceuticals Inc. (San Francisco, Calif.) raised $22 million in a series

Read the full 181 word article

User Sign In